TrialAdvances in therapy2018

Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.

Piercarlo Sarzi-Puttini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.